Sanara Medtech Inc

SMTI remains in a Stage 2 advancing phase, making sequential higher highs and higher lows above rising EMAs and having reclaimed both the 50 DMA and 200 DMA. Short-term momentum is supported by price tightly tracking the rising 9 and 20 EMAs without exhaustion signals despite an overbought tag. With clear demand dominance and supportive intermediate structure, execution favors Buy Now participation on shallow pullbacks into the EMA confluence near former resistance.

• ↑Q1 net revenue reached $27.4 M, up 19% YoY
• ↑Gross margin improved to 93%, net income $0.4 M
• ↓Negative earnings yield and 14% opex rise pressure profits